Windlas Biotech Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v592vg912lvut3b8x06ebxpo.pdf

Key Takeaways


Injectable Facility: The Big Bet, Still Unscored

Hitesh Windlass: "We are looking to ramp up. And obviously, our goal is to achieve that in the fastest possible way. And so we are on the job and expecting to build this business strongly in the future. Exactly how and when and what will be -- we'll be able to achieve, that is something that we are not discussing, although obviously, we have internal targets for everything."

Trade Generics: Scaling Ambition, Distributed Model

Hitesh Windlass: "From our perspective, we really look at trade generics as a very strong space. And there is no reason why Windlas should also not aspire to reach the levels at which Cipla and Alkem are today. They are at INR2,000-plus crores. So why shouldn't a good manufacturer like us who has the opportunities, who understands the products and is able to build sustainably."

CDMO & Exports: The Core Engine


Margins & Costs: Wage Hit, Leverage Offset


Balance Sheet & Capital Allocation

Komal Gupta: "If we get an opportunity which fits in properly, synergistic fit, we would go ahead and do that. As you also mentioned, we have sufficient cash in place and debt taking capability is also there. So there is no restriction in terms of size."

Guidance & Commitments

CommitmentSpecificsTimeline
Plant 6 commercializationOral solids facility ready and operationalWithin FY26
Plant 6 capexCapex spending on Plant 6 retrofitDuring FY26
Depreciation levelINR8.3 crores per quarter sustainableUntil Plant 6 is capitalized
Dividend policyContinue paying ~20% of profitsOngoing, barring exceptions
Trade generics stockist expansionExpand from ~1,000 to 5,000-6,000 stockistsNo timeline given
Injectable sales mix shift to exportsPrioritize exports for stronger marginsLonger term

Key Metrics

MetricQ4 FY25
Revenue₹202.7 cr, +18.3% YoY, ninth straight quarter of record revenue
FY25 Revenue₹759 cr, +20.4% YoY
EBITDA₹25.5 cr, +16% YoY
FY25 EBITDA₹94.1 cr, +20% YoY
PAT₹16.3 cr, vs ₹17 cr in Q4 FY24
FY25 PAT₹61 cr, vs ₹58.2 cr in FY24
EPS (FY25)₹29.19, highest ever post listing
Generic Formulations CDMO revenue₹147.2 cr, +15% YoY
Trade Generics & Institutional revenue₹45.5 cr, +31% YoY
Exports revenue₹10 cr, +12% YoY
Working capital days14 days
ROCE and ROEgreater than 20%, sustained alongside capacity expansion
Liquidity₹213 cr
Oral solids capacity utilization60% to 62% in FY25
Depreciation₹8.3 cr for the quarter, includes Plant 2 extension and injectables
Injectable revenue~₹6 cr, largely from Q4 FY25
Trade generics chronic vs acute mix60% chronic and sub-chronic, 40% acute